NCT00384397View on ClinicalTrials.gov

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

PHASE3CompletedINTERVENTIONAL
Enrollment

1,128

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

February 28, 2009

Conditions
Meningococcal MeningitisMeaslesMumpsRubellaVaricella
Interventions
BIOLOGICAL

Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

0.5 mL, Intramuscular

BIOLOGICAL

Meningococcal Polysaccharide Diphtheria Toxoid Conjugate

0.5 mL, Intramuscular

BIOLOGICAL

Meningococcal Polysaccharide Diphtheria Toxoid Conjugate

0.5 mL, Intramuscular

Trial Locations (39)

13210

Syracuse

14620

Rochester

15241

Pittsburgh

18960

Sellersville

22911

Charlottesville

23113

Midlothian

23510

Norfolk

27514

Chapel Hill

27534

Goldsboro

28352

Laurinburg

28779

Sylva

30062

Marietta

30322

Atlanta

32931

Cocoa Beach

32955

Viera

36106

Montgomery

37660

Kingsport

40004

Bardstown

43205

Columbus

44106

Cleveland

54601

La Crosse

63044

Bridgeton

63141

St Louis

72205

Little Rock

72401

Jonesboro

72703

Fayetteville

74127

Tulsa

76107

Fort Worth

84041

Layton

84062

Pleasant Grove

84123

Salt Lake City

84405

Ogden

84604

Provo

89104

Las Vegas

99220

Spokane

72202-3591

Little Rock

06360

Norwich

01801

Woburn

45229-3039

Cincinnati

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00384397 - A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers | Biotech Hunter | Biotech Hunter